Best Pharma Stocks in June 2026 Based on 5‑Year CAGR: Neuland Laboratories, Caplin Point Laboratories and More

Pharmaceutical companies play a key role in the healthcare ecosystem through the development and manufacturing of medicines, APIs, and specialty products. The sector benefits from export demand, domestic consumption, and increasing focus on high‑value segments such as contract development and manufacturing.

Evaluating stocks using 5‑year CAGR helps identify companies that have delivered consistent long‑term performance. Based on data for June 2026, the following pharma stocks stand out on this metric.

Best Pharma Stocks Based on 5‑Year CAGR

Note: Data as of June 2, 2026

Neuland Laboratories

Neuland Laboratories operates in active pharmaceutical ingredients and contract development and manufacturing services for global clients. The company has reported a 5‑year CAGR of 52.79% along with an ROE of 18.53% and ROCE of 29.92%.

It maintains a debt‑to‑equity ratio of 0.10 and profitability is reflected in EBITDA and net profit margins of 29.45% and 17.73%. Business performance is linked to demand in high‑value APIs and CDMO services across regulated markets.

Caplin Point Laboratories

Caplin Point Laboratories focuses on pharmaceutical formulations and APIs with significant presence in emerging markets. The company has delivered a 5‑year CAGR of 29.35% supported by export growth and branded generics.

It operates with zero debt while reporting ROE of 20.50% and ROCE of 27.69%. Profitability remains strong with EBITDA and net profit margins at 38.06% and 27.85%.

Marksans Pharma

Marksans Pharma manufactures and markets pharmaceutical formulations with exposure to regulated markets such as the US and UK. The stock has delivered a 5‑year CAGR of 29.33% driven by export growth and product expansion.

The company reported ROE of 16.64% and ROCE of 21.17% while maintaining a debt‑to‑equity ratio of 0.13. Its EBITDA margin stood at 22.53% with a net profit margin of 13.78%.

Glenmark Pharmaceuticals

Glenmark Pharmaceuticals operates across generics, branded formulations, and specialty products with a global presence. The company has delivered a 5‑year CAGR of 28.81% supported by business recovery and expansion.

It reported ROE of 12.54% and ROCE of 21.88% along with a debt‑to‑equity ratio of 0.28. EBITDA and net profit margins stood at 15.86% and 7.81% respectively.

Torrent Pharmaceuticals

Torrent Pharmaceuticals focuses on chronic therapies and has operations across domestic and international markets. The company has delivered a 5‑year CAGR of 26.16% along with ROE of 17.19%.

ROCE stood at 9.24% and the debt‑to‑equity ratio was 0.85. The company reported EBITDA margin of 22.82% and net profit margin of 11.28%.

Wockhardt

Wockhardt operates in pharmaceuticals and biotechnology with exposure to formulations, vaccines, and APIs. The stock has delivered a 5‑year CAGR of 25.54% despite variability in earnings.

The company reported a negative ROE of -1.13% while ROCE stood at 7.44%. Its financial profile includes a debt‑to‑equity ratio of 0.43, EBITDA margin of 19.46%, and net profit margin of 6.11%.

J B Chemicals and Pharmaceuticals

J B Chemicals and Pharmaceuticals manufactures formulations across therapeutic segments such as cardiology and gastroenterology. The company has delivered a 5‑year CAGR of 23.69% supported by domestic and international operations.

It operates debt‑free with ROE of 18.69% and ROCE of 21.92%. EBITDA margin was 27.10% and net profit margin stood at 16.86%.

Sun Pharmaceutical Industries

Sun Pharmaceutical Industries is India’s largest pharmaceutical company with a diversified global portfolio. The stock has delivered a 5‑year CAGR of 21.47% supported by scale and product mix.

The company reported ROE of 15.66% and ROCE of 20.97% with a low debt‑to‑equity ratio of 0.03. Profitability remains strong with EBITDA margin of 30.44% and net profit margin of 19.00%.

Ajanta Pharma

Ajanta Pharma focuses on branded generics across therapeutic areas such as cardiology, dermatology, and ophthalmology. The company has delivered a 5‑year CAGR of 18.69% supported by domestic and emerging market growth. .

It reported ROE of 25.02% and ROCE of 35.66% with a debt‑to‑equity ratio of 0.01. EBITDA margin was 27.86% and net profit margin stood at 18.77%.

Laurus Labs

Laurus Labs operates across APIs, formulations, biotechnology, and contract manufacturing services. The stock has delivered a 5‑year CAGR of 18.47% supported by expansion in CDMO and specialty segments.

The company reported ROE of 8.22% and ROCE of 23.34% with a debt‑to‑equity ratio of 0.60. EBITDA margin stood at 26.68% and net profit margin at 12.94%.

Read More: Best Debt‑Free Stocks in June 2026 Based on 5‑Year CAGR.

Want to track these market movements in Hindi? Visit Angel One News for daily updates and comprehensive share market news in Hindi.

Conclusion

Pharma stocks in this list reflect a mix of API manufacturers, formulation companies, and globally diversified pharmaceutical players. Their performance over the 5‑year period is driven by export growth, specialty segments, and contract manufacturing opportunities.

Financial metrics such as margins, return ratios, and leverage levels vary across companies depending on business models. As of June 2026, these stocks provide a snapshot of long‑term growth trends within the pharmaceutical sector.

Investors looking to explore investment opportunities can open a demat account to invest and trade in the equity market seamlessly.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.